ABSTRACT
OBJECTIVE: To determine plasma pharmacokinetics of penciclovir following oral and rectal administration of famciclovir to young Asian elephants (Elephas maximus). ANIMALS: 6 healthy Asian elephants (5 females and 1 male), 4.5 to 9 years old and weighing 1,646 to 2,438 kg. PROCEDURES: Famciclovir was administered orally or rectally in accordance with an incomplete crossover design. Three treatment groups, each comprising 4 elephants, received single doses of famciclovir (5 mg/kg, PO, or 5 or 15 mg/kg, rectally); there was a minimum 12-week washout period between subsequent famciclovir administrations. Serial blood samples were collected after each administration. Samples were analyzed for famciclovir and penciclovir with a validated liquid chromatography-mass spectroscopy assay. RESULTS: Famciclovir was tolerated well for both routes of administration and underwent complete biotransformation to the active metabolite, penciclovir. Mean maximum plasma concentration of penciclovir was 1.3 µg/mL at 1.1 hours after oral administration of 5 mg/kg. Similar results were detected after rectal administration of 5 mg/kg. Mean maximum plasma concentration was 3.6 µg/mL at 0.66 hours after rectal administration of 15 mg/kg; this concentration was similar to results reported for humans receiving 7 mg/kg orally. CONCLUSIONS AND CLINICAL RELEVANCE: Juvenile Asian elephants are susceptible to elephant endotheliotropic herpesvirus. Although most infections are fatal, case reports indicate administration of famciclovir has been associated with survival of 3 elephants. In Asian elephants, a dose of 8 to 15 mg of famciclovir/kg given orally or rectally at least every 8 hours may result in penciclovir concentrations that are considered therapeutic in humans.
Subject(s)
2-Aminopurine/analogs & derivatives , Acyclovir/analogs & derivatives , Antiviral Agents/pharmacokinetics , Elephants/metabolism , 2-Aminopurine/administration & dosage , 2-Aminopurine/blood , 2-Aminopurine/pharmacokinetics , Acyclovir/administration & dosage , Acyclovir/blood , Acyclovir/pharmacokinetics , Administration, Oral , Administration, Rectal , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Area Under Curve , Chromatography, Liquid , Cross-Over Studies , Famciclovir , Female , Guanine , Half-Life , Male , Mass SpectrometryABSTRACT
Captive Asian elephants (Elephas maximus) are susceptible to lameness resulting from foot and joint pain, including chronic arthritis. In the past, opioid analgesics, such as butorphanol, have been used clinically for pain management. However, dosages used in treating elephants were often extrapolated from data in horses, with no pharmacokinetic information on the specific agents used in elephant species. In this pharmacokinetic study, six adult captive Asian elephants (5 female, 1 male castrate) were administered a 0.015 mg/kg dose of butorphanol by both i.v. and i.m. routes. A complete crossover design was used with a 3-wk washout period between treatments. Serial blood samples were collected immediately prior to butorphanol administration and at 5, 10, 20, and 40 min and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 24 h after administration. The butorphanol analysis was performed using a validated liquid chromatography-mass spectrophotometric assay with a limit of quantitation of 0.025 ng/ml. The mean Cmax after i.m. administration was 7.9 ng/ml, with a corresponding Tmax, of 40 min and t(1/3), of 7.1 h. After i.v. administration, the mean Vd(ss) was 1.4 L/kg and the mean Cl(p) was 0.26 L/kg/h. Mean i.m. bioavailability was 37%. The results indicate that butorphanol used at 0.015 mg/kg i.m. or i.v. could be useful in elephants when given for pain control.
Subject(s)
Analgesics, Opioid/administration & dosage , Analgesics, Opioid/pharmacokinetics , Butorphanol/administration & dosage , Butorphanol/pharmacokinetics , Elephants/blood , Analgesics, Opioid/blood , Analgesics, Opioid/metabolism , Animals , Area Under Curve , Biological Availability , Butorphanol/blood , Butorphanol/metabolism , Cross-Over Studies , Female , Half-Life , Injections, Intramuscular , Injections, Intravenous , MaleABSTRACT
Peroxidase-mediated oxidation has been proposed as a treatment method for naphthol-contaminated water. However, the impact of solution chemistry on naphthol polymerization and removal has not been documented. This research investigated the impact of pH and ionic strength on peroxidase-mediated removal of 1-naphthol in completely mixed batch reactors. The impact of hydrogen peroxide to 1-naphthol ratio and activity of horseradish peroxidase was also studied. Size exclusion chromatography was used to estimate the molecular weight distribution of oligomeric products, and liquid chromatography/mass spectrometry was used to estimate product structure. Naphthol transformation decreased with ionic strength, and substrate removal was lowest at neutral pHs. Solution pH influenced the size and the composition of the oligomeric products. An equimolar ratio of H(2)O(2):naphthol was sufficient for optimal naphthol removal. Polymerization products included naphthoquinones and oligomers derived from two, three, and four naphthol molecules. Our results illustrate the importance of water chemistry when considering a peroxidase-based approach for treatment of naphthol-contaminated waters.
Subject(s)
Naphthols/chemistry , Peroxidase/chemistry , Chromatography, Liquid , Horseradish Peroxidase/chemistry , Hydrogen Peroxide/chemistry , Hydrogen-Ion Concentration , Mass Spectrometry , Osmolar Concentration , Water PurificationABSTRACT
OBJECTIVE-To determine the pharmacokinetics of marbofloxacin after oral administration every 24 hours to rabbits during a 10-day period. ANIMALS-8 healthy 9-month-old female New Zealand White rabbits. PROCEDURES-Marbofloxacin (5 mg/kg) was administered orally every 24 hours to 8 rabbits for 10 days. The first day of administration was designated as day 1. Blood samples were obtained at 0, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours on days 1 and 10 of marbofloxacin administration. Plasma marbofloxacin concentrations were quantitated by use of a validated liquid chromatography-mass spectrometry assay. Pharmacokinetic analysis of marbofloxacin was analyzed via noncompartmental methods. RESULTS-After oral administration, mean +/- SD area under the curve was 10.50 +/- 2.00 microg.h/mL and 10.90 +/- 2.45 microg.h/mL, maximum plasma concentration was 1.73 +/- 0.35 microg/mL and 2.56 +/- 0.71 microg/mL, and harmonic mean terminal half-life was 8.0 hours and 3.9 hours for days 0 and 10, respectively. CONCLUSIONS AND CLINICAL RELEVANCE-Marbofloxacin administered orally every 24 hours for 10 days appeared to be absorbed well and tolerated by rabbits. Administration of marbofloxacin at a dosage of 5 mg/kg, PO, every 24 hours is recommended for rabbits to control infections attributable to susceptible bacteria.
Subject(s)
Enzyme Inhibitors/pharmacokinetics , Fluoroquinolones/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/blood , Female , Fluoroquinolones/administration & dosage , Fluoroquinolones/blood , Half-Life , Rabbits , Time FactorsABSTRACT
The nonsteroidal anti-inflammatory drug (NSAID) meloxicam is a very popular anti-inflammatory, analgesic, and antipyretic agent used in veterinary medicine. To determine the pharmacokinetics of this NSAID in rabbits following a single dose and 10-day period of dosing, eight clinically normal, 8-mo-old New Zealand white rabbits (Oryctolagus cuniculus) were administered 0.2 mg/kg meloxicam p.o. daily. Pharmacokinetic analysis of the meloxicam was determined via noncompartmental analysis. After oral administration, mean +/- standard deviation values for area under the curve were 1.8 +/- 0.50 and 2.1 +/- 0.55 microg x h/ml, and maximum plasma concentrations were 0.17 +/- 0.06 and 0.24 +/- 0.07 microg/ml for Day 1 and Day 10, respectively. The half-life was approximately 8 hr. Administration of meloxicam at a dosage of 0.2 to 0.3 mg/kg p.o. every 24 hr is suggested. Although a higher dose may be required for optimum effects, this would require efficacy and safety studies in this species. Meloxicam administered at 0.2 mg/kg p.o. daily for 10 day was well tolerated by the rabbits.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Thiazines/pharmacokinetics , Thiazoles/pharmacokinetics , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Area Under Curve , Drug Administration Schedule , Female , Half-Life , Meloxicam , Rabbits , Thiazines/administration & dosage , Thiazines/blood , Thiazoles/administration & dosage , Thiazoles/bloodABSTRACT
Hantaviruses may cause serious disease when transmitted to humans by their rodent hosts. Since their emergence in the Americas in 1993, there have been extensive efforts to understand the role of environmental factors on the presence of these viruses in their host rodent populations. HPS outbreaks have been linked to precipitation, but climatic factors alone have not been sufficient to predict the spatial-temporal dynamics of the environment-reservoir-virus system. Using a series of mark-recapture sampling sites located at the Mbaracayú Biosphere Reserve, an Atlantic Forest site in eastern Paraguay, we investigated the hypothesis that microhabitat might also influence the prevalence of Jaborá hantavirus within populations of its reservoir species, Akodon montensis. Seven trapping sessions were conducted during 2005-2006 at four sites chosen to capture variable microhabitat conditions within the study site. Analysis of microhabitat preferences showed that A. montensis preferred areas with little forest overstory and denser vegetation cover on and near the ground. Moreover, there was a significant difference in the microhabitat occupied by antibody-positive vs antibody-negative rodents, indicating that microhabitats with greater overstory cover may promote transmission and maintenance of hantavirus in A. montensis.
Subject(s)
Arvicolinae/virology , Disease Reservoirs/virology , Ecosystem , Hantavirus Infections/veterinary , Orthohantavirus/immunology , Animals , Antibodies, Viral/blood , Arvicolinae/physiology , Hantavirus Infections/virology , Paraguay , Risk Factors , Seroepidemiologic Studies , TreesABSTRACT
Landscape epidemiology has made significant strides recently, driven in part by increasing availability of land cover data derived from remotely-sensed imagery. Using an example from a study of land cover effects on hantavirus dynamics at an Atlantic Forest site in eastern Paraguay, we demonstrate how automated classification methods can be used to stratify remotely-sensed land cover for studies of infectious disease dynamics. For this application, it was necessary to develop a scheme that could yield both land cover and land use data from the same classification. Hypothesizing that automated discrimination between classes would be more accurate using an object-based method compared to a per-pixel method, we used a single Landsat Enhanced Thematic Mapper+ (ETM+) image to classify land cover into eight classes using both per-pixel and object-based classification algorithms. Our results show that the object-based method achieves 84% overall accuracy, compared to only 43% using the per-pixel method. Producer's and user's accuracies for the object-based map were higher for every class compared to the per-pixel classification. The Kappa statistic was also significantly higher for the object-based classification. These results show the importance of using image information from domains beyond the spectral domain, and also illustrate the importance of object-based techniques for remote sensing applications in epidemiological studies.
Subject(s)
Agriculture/classification , Ecology , Hantavirus Infections/parasitology , Photography , Spacecraft , Animals , Communicable Diseases , Ecosystem , Orthohantavirus , Hantavirus Infections/epidemiology , Paraguay/epidemiology , Risk AssessmentABSTRACT
OBJECTIVE: To determine the pharmacokinetics of marbofloxacin after single IV and orally administered doses in blue and gold macaws. ANIMALS: 10 healthy blue and gold macaws. PROCEDURES: In a crossover study, marbofloxacin (2.5 mg/kg) was administered orally (via crop gavage) to 5 birds and IV to 5 birds. Blood samples were obtained at 0, 0.5, 1, 3, 6, 12, 24, 48, 72, and 96 hours after marbofloxacin administration. After a 4-week washout period, the study was repeated, with the first 5 birds receiving the dose IV and the second 5 birds receiving the dose orally. Serum marbofloxacin concentrations were quantitated by use of a validated liquid chromatography-mass spectrometry assay. RESULTS: After oral administration, mean +/- SD area under the curve was 7.94 +/- 2.08 microg.h/mL, maximum plasma concentration was 1.08 +/- 0.316 microg/mL, and bioavailability was 90.0 +/- 31%. After IV administration of marbofloxacin, the apparent volume of distribution was 1.3 +/- 0.32 L/kg, plasma clearance was 0.29 +/- 0.078 L/h/kg, area under the curve was 9.41 +/- 2.84 microg.h/mL, and the harmonic mean terminal half-life was 4.3 hours. CONCLUSIONS AND CLINICAL RELEVANCE: Single IV and orally administered doses of marbofloxacin were well tolerated by blue and gold macaws. The orally administered dose was well absorbed. Administration of marbofloxacin at a dosage of 2.5 mg/kg, PO, every 24 hours may be appropriate to control bacterial infections susceptible to marbofloxacin in this species.
Subject(s)
Fluoroquinolones/administration & dosage , Fluoroquinolones/pharmacokinetics , Psittaciformes/metabolism , Quinolones/administration & dosage , Quinolones/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Biological Availability , Female , Fluoroquinolones/blood , Half-Life , Injections, Intravenous , Male , Psittaciformes/blood , Quinolones/bloodABSTRACT
Pharmacokinetics of marbofloxacin in two male and four female adult ball pythons (Python regius) was determined after i.v. and p.o. administration of a single dose. Using a crossover design, each snake was given a single 10 mg/kg dose of marbofloxacin i.v. and p.o. Blood samples were collected prior to and 0.5, 1, 1.5, 3, 6, 12, and 24 hr after marbofloxacin administration. Marbofloxacin was quantitated by use of liquid chromatography-mass spectrometry. Following p.o. administration, marbofloxacin had a peak plasma concentration (Cmax) of 9.40 microg/ml and a time to Cmax (Tmax) of 9.0 hr. Based on the plasma pharmacokinetics generated in this study and pending any further studies to evaluate potential toxicity and multi-dose pharmacokinetics, we suggest a dosage for marbofloxacin in ball pythons of 10 mg/kg p.o. at least every 48 hr, depending on the sensitivity of the pathogen and as a basis for further research.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Boidae/blood , Fluoroquinolones/pharmacokinetics , Quinolones/pharmacokinetics , Administration, Oral , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/metabolism , Area Under Curve , Biological Availability , Boidae/metabolism , Chromatography, Liquid/veterinary , Cross-Over Studies , Female , Fluoroquinolones/blood , Fluoroquinolones/metabolism , Injections, Intravenous/veterinary , Male , Mass Spectrometry/veterinary , Quinolones/blood , Quinolones/metabolismABSTRACT
The pharmacokinetic parameters of carfentanil and naltrexone were determined in the common eland (Taurotragus oryx). Six adult females were immobilized with xylazine (0.23 +/- 0.03 mg/kg i.m.) and carfentanil (0.0169 +/- 0.0005 mg/kg i.m.) for a 45-min period, during which time routine health care procedures were performed. Heart and respiration rates and body temperatures were monitored throughout the immobilization period. A single intramuscular injection of naltrexone (1.66 +/- 0.08 mg/kg i.m.) was sufficient for reversal. The eland were intermittently restrained in a hydraulic squeeze chute for serial blood sample collection via jugular venipuncture during immobilization and up to 48 hr post-immobilization. The quantification of carfentanil and naltrexone in the plasma was performed by liquid chromatography and mass spectroscopy methods. Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C(max)) at 13.8 min. Naltrexone was readily absorbed and reached C(max) at 23.4 +/- 16.8 min after administration. All animals stood 2.7 +/- 2.2 min after naltrexone administration. Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr. Although respiratory rates appeared to fluctuate widely among animals, heart rates and body temperature remained stable throughout the immobilization. Renarcotization was not noted as a major complication.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Antelopes/physiology , Fentanyl/analogs & derivatives , Immobilization/veterinary , Naltrexone/pharmacokinetics , Narcotic Antagonists/pharmacokinetics , Analgesics, Opioid/administration & dosage , Animals , Antelopes/blood , Antelopes/metabolism , Area Under Curve , Body Temperature/drug effects , Female , Fentanyl/administration & dosage , Fentanyl/pharmacokinetics , Gas Chromatography-Mass Spectrometry/veterinary , Half-Life , Heart Rate/drug effects , Immobilization/methods , Injections, Intramuscular/veterinary , Metabolic Clearance Rate , Naltrexone/administration & dosage , Narcotic Antagonists/administration & dosage , Random Allocation , Respiration/drug effectsABSTRACT
OBJECTIVE: To determine the plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in Greyhounds. ANIMALS: 7 adult Greyhounds. PROCEDURES: Dogs received celecoxib (median dose, 11.8 mg/kg [range, 11.5 to 13.6 mg/kg], PO, q 24 h) for 10 days. Blood samples were collected prior to administration of celecoxib and serially for 24 hours after the 1st and 10th doses were administered. A synovial joint catheter was placed into a stifle joint in each dog for collection of synovial fluid samples. Concentrations of celecoxib in plasma and synovial fluid were quantified by use of a validated liquid chromatography/mass spectrometry method. Identification of hydroxy- and carboxyl-celecoxib in plasma and synovial fluid was also performed. Pharmacokinetic parameters were determined by use of noncompartmental analysis. RESULTS: Administration of multiple doses of celecoxib resulted in a significant decrease (40%) in median area under the curve (AUC) values and a corresponding decrease in median maximum concentrations (Cmax; 2,620 to 2,032 ng/mL) between the 1st and 10th doses. Synovial fluid concentrations were less than the corresponding plasma concentrations at all times except 24 hours after administration of the 10th dose of celecoxib. CONCLUSIONS AND CLINICAL RELEVANCE: Celecoxib distributes into the synovial fluid of Greyhounds. Although the exact mechanism for the decreases in AUC and Cmax is not known, results suggested that the plasma pharmacokinetics of celecoxib are different after administration of multiple doses in Greyhounds. These findings warrant further investigation on the absorption, distribution, metabolism, and elimination of celecoxib in Greyhounds and other breeds of dogs.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Dogs/metabolism , Pyrazoles/pharmacokinetics , Sulfonamides/pharmacokinetics , Synovial Fluid/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/analysis , Anti-Inflammatory Agents, Non-Steroidal/blood , Area Under Curve , Celecoxib , Dogs/blood , Female , Male , Pyrazoles/analysis , Pyrazoles/blood , Sulfonamides/analysis , Sulfonamides/blood , Tissue DistributionABSTRACT
The oxidative polymerization of 1-naphthol was investigated in the presence of horseradish peroxidase (HRP). Naphthol polymerization products (NPP) were characterized for their relative polarity using octanol--water partitioning experiments and reverse-phase high pressure liquid chromatography, for structure using size exclusion chromatography and liquid chromatography-mass spectrometry (LC/MS), and for ecotoxicity using inhibition of bacterial bioluminescence. Peroxidase addition resulted in the production of soluble and insoluble NPP. Soluble NPP was predominantly more polar than the parent naphthol and comprised of trimers and tetramers. Insoluble NPP oligomers included dimers, trimers and tetramers. The net aqueous-phase toxicity was significantly reduced due to polymer formation and subsequent precipitation. A reaction model deduced from the LC/MS fragmentation patterns of trimeric naphthol was proposed for NPP formation. Results from this study suggest that HRP-mediated treatment of naphthol contaminated soils can achieve risk reduction through (i) the formation of large hydrophobic oligomers that are immobilized on the soil matrix; and (ii) reduction in aqueous-phase toxicity due to polymer precipitation.
Subject(s)
Horseradish Peroxidase/metabolism , Naphthols/chemistry , Naphthols/metabolism , Horseradish Peroxidase/chemistry , Models, Chemical , Molecular Structure , PolymersABSTRACT
Azithromycin is a broad spectrum antimicrobial agent that is approved in the United States for use in humans. Due to azithromycin's low rate of metabolism it is likely to be found in wastewater treatment plants, where its broad spectrum of antimicrobial activity could lead to development of resistance in bacteria. A liquid-liquid extraction using K2CO3 and methyl-t-butyl ether (MTBE) was used to extract azithromycin from 10 ml aliquots of wastewater. Liquid chromatography was performed using a Luna C18(2) (30 mm x 2.0 mm) column with a mass spectrometer friendly mobile phase containing 50:24:2:24 acetonitrile, methanol, tetrahydrofuran, and 0.04 M ammonium hydroxide. The mass spectrometer used an electrospray source with positive ionization and an ion trap detector. A linear standard curve from 5 to 200pg/ml was validated and used to quantitate azithromycin in wastewater.
Subject(s)
Azithromycin/analysis , Azithromycin/isolation & purification , Water Pollutants/analysis , Chromatography, Liquid/methods , Mass Spectrometry , Sensitivity and Specificity , Waste Disposal, FluidABSTRACT
Azithromycin is classified as an azalide, a subclass of macrolide antimicrobials with a broad spectrum of activity in vitro against many potential bacterial pathogens including spirochetes, anaerobes, and Chlamydia trachomatis. Because of limited data on the use of azithromycin in avian medicine, this study was designed to determine the pharmacokinetics of azithromycin in blue and gold macaws (Ara ararauna), a species commonly seen in clinical practice. Azithromycin (10 mg/kg) was administered via crop lavage to five birds and intravenously to five birds, and blood samples were obtained at 0, 0.5, 1, 3, 6, 12, 24, 48, 72, and 96 hr post-azithromycin administration. Following a 4-wk washout period, the study was repeated with a complete crossover study performed. Concentration of azithromycin in plasma samples was quantified using a validated liquid chromatography/mass spectrometry assay. Pharmacokinetic parameters were determined using noncompartmental analysis. Based on the pharmacokinetic data generated from this study, a starting dose of azithromycin at 10 mg/kg p.o. every 48 hr for susceptible bacterial infections in blue and gold macaws is recommended.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Azithromycin/pharmacokinetics , Birds/blood , Administration, Oral , Animals , Area Under Curve , Birds/metabolism , Cross-Over Studies , Female , Injections, Intravenous/veterinary , Male , Random AllocationABSTRACT
Three captive loggerhead sea turtles, Caretta caretta, were used in four trials, one i.v. and three i.m., to determine the pharmacokinetic properties of a single dose of ticarcillin. For the i.v. study, each turtle received a single 50 mg/kg dose and blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, and 12 hr and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 14 days after administration. For the i.m. study, each turtle received one of three dosages (25, 50, or 100 mg/kg) in a randomized complete block design and blood samples were collected at the same time intervals. Each trial was separated by a minimum of 28 days to allow for complete drug clearance. Drug concentration in plasma was determined by a validated liquid chromatography-mass spectrometry assay. For the i.v. study, the elimination half-life was 5.0 hr. The apparent volume of distribution and plasma clearance were 0.17 L/kg and 0.0218 L/hr/kg, respectively. For the i.m. study, mean time to maximum plasma concentrations ranged from 1.7 ( +/- 0.58) hr in the 50 mg/kg group to 3.7 (+/- 2.5) hr in the 100 mg/kg group. Mean bioavailability ranged from 45% ( +/- 15%) in the 50 mg/kg group to 58% (+/- 12%) in the 100 mg/kg group, and the mean residence time ranged from 7.5 ( +/- 2.6) hr in the 25 mg/kg group to 16 (+/- 6.8) hr in the 100 mg/kg group. Two turtles had slight alanine aminotransferase elevations that were not clinically apparent at two different dosages, but otherwise, blood chemistries were unaffected. Possible i.m. dosage regimens for loggerhead sea turtles are 50 mg/kg q24 hr or 100 mg/kg q48 hr. Liver enzymes should be monitored during treatment.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Ticarcillin/pharmacokinetics , Turtles , Animals , Area Under Curve , Biological Availability , Blood Chemical Analysis/veterinary , Cross-Over Studies , Dose-Response Relationship, Drug , Female , Injections, Intramuscular/veterinary , Injections, Intravenous/veterinary , Metabolic Clearance Rate , Random Allocation , Turtles/blood , Turtles/physiologyABSTRACT
Fentanyl is approved for transmucosal use in the United States as a preanesthetic agent in human pediatric patients and in adults for breakthrough cancer pain. Using this formulation in three species of great ape, including eight orangutans (Pongo pygmaeus), nine chimpanzees (Pan troglodytes), and two gorillas (Gorilla gorilla), fentanyl was offered transmucosally at an intended dose of 10-15 microg/kg based on estimated body weight. The animals were trained to accept and suck slowly on a piece of placebo candy, given as a treat, after an overnight fast. On the day of the study, the animals were given the lollipop formulation of fentanyl. The resulting plasma concentrations of fentanyl supported transmucosal absorption, similar to that reported in humans. This study provides an alternative sedative regimen and yielded half-life data of transmucosal fentanyl in great apes. Although transmucosal fentanyl was a useful adjunct for sedating orangutans and gorillas, its acceptance by chimpanzees before chemical immobilization was suboptimal and unpredictable.
Subject(s)
Adjuvants, Anesthesia/pharmacokinetics , Fentanyl/pharmacokinetics , Gorilla gorilla/physiology , Pan troglodytes/physiology , Pongo pygmaeus/physiology , Adjuvants, Anesthesia/administration & dosage , Administration, Buccal , Administration, Oral , Animals , Animals, Zoo , Dose-Response Relationship, Drug , Female , Fentanyl/administration & dosage , Male , Mouth Mucosa/metabolism , Safety , Time FactorsABSTRACT
Using a crossover study design, the pharmacokinetics of carfentanil and naltrexone after i.v., i.m., and s.c. administration were determined in eight domestic goats (Capra hircus). Serial blood samples were taken up to 120 hr after carfentanil administration, and the plasma drug concentrations were determined using liquid chromatography and mass spectroscopy. All goats were immobilized with 40 microg/kg carfentanil i.m., although the resulting neurologic effects varied considerably. Plasma profiles showed rapid carfentanil absorption and a simple biphasic decline for 12-48 hr. Naltrexone given at 100 mg naltrexone/mg carfentanil 30 min after carfentanil administration produced rapid reversal of immobilization after all routes of administration. Variable fluctuations in the naltrexone plasma concentrations during the first 2.5-3.5 hr were observed, followed by a more consistent biphasic decline. The time to standing was significantly shorter after i.v. compared with s.c. naltrexone, although the time difference (1 min) had little clinical relevance. No statistically significant differences between the naltrexone pharmacokinetic parameters measured for the three routes of naltrexone administration were identified, although the recoveries after i.m. administration were, subjectively, the smoothest. The carfentanil half-life did not differ significantly in the goats given naltrexone by different routes. Although it is currently recommended that the naltrexone dose be divided into s.c. and i.v. portions, this practice does not appear to offer any benefit.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Fentanyl/analogs & derivatives , Fentanyl/pharmacokinetics , Goats/metabolism , Immobilization/veterinary , Naltrexone/pharmacokinetics , Narcotic Antagonists/pharmacokinetics , Absorption/drug effects , Analgesics, Opioid/administration & dosage , Animals , Cross-Over Studies , Female , Fentanyl/administration & dosage , Gas Chromatography-Mass Spectrometry/methods , Gas Chromatography-Mass Spectrometry/veterinary , Goats/blood , Goats/physiology , Half-Life , Immobilization/methods , Injections, Intramuscular/veterinary , Injections, Intravenous/veterinary , Injections, Subcutaneous/veterinary , Male , Metabolic Clearance Rate , Naltrexone/administration & dosage , Narcotic Antagonists/administration & dosage , Random AllocationABSTRACT
This method is the first analytical method for the detection and quantitation of carfentanil and naltrexone at clinically relevant concentrations using liquid chromatography-mass spectrometry. Samples were alkalinized with 100 microl of 1 M NaOH and extracted 2x with 2 ml of toluene. The extractions were combined and dried under N(2) at 40 degrees C in a H(2)O bath. Chromatography was performed using a Zirchrom PBD column and a mobile phase of 30:70 acetonitrile/10 mM ammonium acetate and 0.1 mM citrate (pH=4.4) at a flow rate of 0.3 ml/min. The lower limit of quantitation was 8.5 pg/ml for carfentanil and 0.21 ng/ml for naltrexone.
Subject(s)
Analgesics, Opioid/blood , Chromatography, Liquid/methods , Fentanyl/analogs & derivatives , Fentanyl/blood , Naltrexone/blood , Spectrometry, Mass, Electrospray Ionization/methods , Animals , Goats , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
OBJECTIVE: To determine pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius) after IV or oral administration of a single dose. ANIMALS: 2 male and 5 female ball pythons. PROCEDURES: Using a crossover design, each snake was given a single dose of azithromycin (10 mg/kg) IV. After a 4-week washout period, each snake was given a single dose of azithromycin (10 mg/kg) orally. Blood samples were collected prior to dose administration and 1, 3, 6, 12, 24, 48, 72, and 96 hours after azithromycin administration. Azithromycin was quantitated by use of liquid chromatography-mass spectrometry. RESULTS: After IV administration, azithromycin had an apparent volume of distribution of 5.69 L/kg and a plasma clearance of 0.19 L/h/kg. Harmonic means for the terminal half-life were 17 hours following IV administration and 51 hours following oral administration. Mean residence times were 37 and 94 hours following IV and oral administration, respectively. Following oral administration, azithromycin had a peak plasma concentration (Cmax) of 1.04 microg/mL, a time to Cmax of 8.4 hours, and a prolonged mean absorption time of 57 hours. Mean oral bioavailability was 77%. Tissue concentrations ranged from 4 to 140 times the corresponding plasma concentration at 24 and 72 hours after azithromycin administration. CONCLUSIONS AND CLINICAL RELEVANCE: Azithromycin is well absorbed and tolerated by ball pythons. On the basis of plasma pharmacokinetics and tissue concentration data, we suggest an azithromycin dosage in ball pythons of 10 mg/kg, orally, every 2 to 7 days, depending upon the site of infection and susceptibil ity of the infective organism.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Azithromycin/pharmacokinetics , Boidae/metabolism , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Azithromycin/administration & dosage , Azithromycin/blood , Biological Availability , Cross-Over Studies , Female , Male , Tissue DistributionABSTRACT
OBJECTIVE: To assess oral bioavailability (F) and pharmacokinetic characteristics of the R- and S-enantiomers of ketoprofen administered IV and orally to captive Asian elephants (Elephas maximus). ANIMALS: 5 adult Asian elephants. PROCEDURE: Elephants received single treatments of racemic ketoprofen at a dose of 2.2 mg/kg, administered IV and orally, in a complete crossover design. Blood samples were collected at intervals during the 24 hours following treatment. At least 4 weeks elapsed between drug administrations. Samples were analyzed for R- and S-ketoprofen with a validated liquid chromatography-mass spectroscopic assay. Pharmacokinetic parameters were determined by use of noncompartmental analysis. RESULTS: The enantiomers of ketoprofen were absorbed well after oral administration, with median F of 101% for R-ketoprofen and 85% for S-ketoprofen. Harmonic mean half-life ranged from 3.8 to 5.5 hours, depending on route of administration and enantiomer. The area under the concentration-time curve, mean residence time, apparent volume of distribution, plasma clearance, and maximum plasma concentration values were all significantly different between the 2 enantiomers for both routes of administration. CONCLUSIONS AND CLINICAL RELEVANCE: Ketoprofen has a long terminal half-life and complete absorption in this species. Based on the pharmacokinetic data, a dosage of ketoprofen of 1 mg/kg every 48 hours to 2 mg/kg every 24 hours, PO or IV, is recommended for use in Asian elephants, although the safety and efficacy of ketoprofen during long-term administration in elephants have not been determined.